{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:06:37Z","timestamp":1788977197550,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100020537","name":"Merck Sharp and Dohme Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021515","name":"Sanofi Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019213","name":"Amgen Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019213","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2026,8,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the characteristics, detection and management of children and adolescents with familial hypercholesterolaemia (FH) enrolled in the Australian National FH Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional registry analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>17 specialist lipid clinics across Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>341 children and adolescents under 18 years of age with FH, enrolled between February 2015 and March 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>None, observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Age at enrolment, mode of FH detection, uptake of genetic testing, lipid-lowering therapy patterns, attainment of low-density lipoprotein-cholesterol (LDL-C) goals and testing of lipoprotein(a) [Lp(a)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age at enrolment was 11.9 years; 51.4% were male and 53.5% were index cases. Only 52.6% had undergone genetic testing. The mean untreated LDL-C was 6.2\u2009mmol\/L. At follow-up, 85.4% were on lipid-lowering therapy, with 91.3% on a moderate-intensity or high-intensity statin but only 12.7% received combination therapy with ezetimibe. The mean treated LDL-C was 3.8\u2009mmol\/L and only 48.3% achieved the guideline-recommended goal. Factors associated with goal attainment included a lower pre-treatment LDL-C and use of lipid-lowering therapy. Lp(a) was tested in only 33.7% of children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals five critical gaps in the care of Australian children with FH: late diagnosis after the recommended age to commence therapy; non-attainment of LDL-C goals despite treatment; under-utilisation of genetic testing; infrequent cascade testing and infrequent testing of Lp(a). Addressing these gaps demands a coordinated multilevel response, including a universal childhood FH screening programme coupled with state-based cascade testing hubs and rigorous implementation of evidence-based paediatric guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2026-331003","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:20:16Z","timestamp":1788974416000},"page":"archdischild-2026-331003","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Paediatric familial hypercholesterolaemia in Australia: a real-world registry study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1038-2837","authenticated-orcid":false,"given":"Andrew C","family":"Martin","sequence":"first","affiliation":[{"name":"Medical School, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of General Paediatrics, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, Children\u2019s Hospital at Westmead, Westmead, New South Wales, Australia"},{"name":"Discipline of Child and Adolescent Health, Faculty of Medicine, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N","family":"Justo","sequence":"additional","affiliation":[{"name":"Queensland Paediatric Cardiac Service, Queensland Children\u2019s Hospital, South Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E","family":"Waddell-Smith","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Women's and Children\u2019s Hospital Adelaide, North Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari E","family":"Horton","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick C","family":"Chan","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9700-6948","authenticated-orcid":false,"given":"Jing","family":"Pang","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-1524","authenticated-orcid":false,"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"},{"name":"Department of Cardiology and Internal Medicine, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026090910201091000_archdischild-2026-331003v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2019.12.002"},{"key":"2026090910201091000_archdischild-2026-331003v1.2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(23)01842-1","article-title":"Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study","volume":"403","author":"Dharmayat","year":"2024","journal-title":"Lancet"},{"key":"2026090910201091000_archdischild-2026-331003v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.03.001"},{"key":"2026090910201091000_archdischild-2026-331003v1.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6807.893"},{"key":"2026090910201091000_archdischild-2026-331003v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"2026090910201091000_archdischild-2026-331003v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816454"},{"key":"2026090910201091000_archdischild-2026-331003v1.7","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jpc.16096","article-title":"Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician","volume":"58","author":"Horton","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"2026090910201091000_archdischild-2026-331003v1.8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.hlc.2020.07.012","article-title":"Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry","volume":"30","author":"Pang","year":"2021","journal-title":"Heart Lung Circ"},{"key":"2026090910201091000_archdischild-2026-331003v1.9","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2008.135"},{"key":"2026090910201091000_archdischild-2026-331003v1.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1754.2011.02102.x"},{"key":"2026090910201091000_archdischild-2026-331003v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2020.09.943"},{"key":"2026090910201091000_archdischild-2026-331003v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"2026090910201091000_archdischild-2026-331003v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2026090910201091000_archdischild-2026-331003v1.14","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1093\/eurheartj\/ehag382","article-title":"Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement","volume":"47","author":"Wiegman","year":"2026","journal-title":"Eur Heart J"},{"key":"2026090910201091000_archdischild-2026-331003v1.15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.arcped.2024.01.004","article-title":"Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort","volume":"31","author":"Peretti","year":"2024","journal-title":"Arch Pediatr"},{"key":"2026090910201091000_archdischild-2026-331003v1.16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacl.2017.11.009","article-title":"Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway","volume":"12","author":"Bogsrud","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026090910201091000_archdischild-2026-331003v1.17","doi-asserted-by":"crossref","unstructured":"Galimberti F , Capra ME , Olmastroni E , et al . Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry. Atherosclerosis 2026;415. doi:10.1016\/j.atherosclerosis.2026.120691","DOI":"10.1016\/j.atherosclerosis.2026.120691"},{"key":"2026090910201091000_archdischild-2026-331003v1.18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.rec.2016.10.010","article-title":"Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry","volume":"70","author":"Saltijeral","year":"2017","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"2026090910201091000_archdischild-2026-331003v1.19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpeds.2020.09.042","article-title":"Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry","volume":"229","author":"de Ferranti","year":"2021","journal-title":"J Pediatr"},{"key":"2026090910201091000_archdischild-2026-331003v1.20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jpc.13898","article-title":"Parent-child genetic testing for familial hypercholesterolaemia in an Australian context","volume":"54","author":"Pang","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"2026090910201091000_archdischild-2026-331003v1.21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/jpc.15426","article-title":"Familial hypercholesterolaemia: Experience of a tertiary paediatric lipid clinic","volume":"57","author":"Yeung","year":"2021","journal-title":"J Paediatr Child Health"},{"key":"2026090910201091000_archdischild-2026-331003v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00892-0"},{"key":"2026090910201091000_archdischild-2026-331003v1.23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S2213-8587(24)00221-3","article-title":"Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study","volume":"12","author":"Elshorbagy","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026090910201091000_archdischild-2026-331003v1.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109191"},{"key":"2026090910201091000_archdischild-2026-331003v1.25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/eurheartj\/ehac660","article-title":"Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study","volume":"44","author":"de Boer","year":"2023","journal-title":"Eur Heart J"},{"key":"2026090910201091000_archdischild-2026-331003v1.26","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jacl.2023.11.007","article-title":"Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia","volume":"18","author":"Loh","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026090910201091000_archdischild-2026-331003v1.27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(23)00156-0","article-title":"Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study","volume":"11","author":"de Boer","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026090910201091000_archdischild-2026-331003v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.05.008"},{"key":"2026090910201091000_archdischild-2026-331003v1.29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2026090910201091000_archdischild-2026-331003v1.30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2014.12.036","article-title":"Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience","volume":"239","author":"Bell","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026090910201091000_archdischild-2026-331003v1.31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41431-025-01979-7","article-title":"Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community","volume":"34","author":"Pang","year":"2026","journal-title":"Eur J Hum Genet"},{"key":"2026090910201091000_archdischild-2026-331003v1.32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacl.2025.03.004","article-title":"Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experience","volume":"19","author":"Sarkies","year":"2025","journal-title":"J Clin Lipidol"},{"key":"2026090910201091000_archdischild-2026-331003v1.33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"292","author":"Ramaswami","year":"2020","journal-title":"Atherosclerosis"},{"key":"2026090910201091000_archdischild-2026-331003v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.07.030"},{"key":"2026090910201091000_archdischild-2026-331003v1.35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2020.11.027","article-title":"Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia","volume":"316","author":"Svendsen","year":"2021","journal-title":"Atherosclerosis"},{"key":"2026090910201091000_archdischild-2026-331003v1.36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpeds.2022.08.041","article-title":"Factors Predicting Statin Initiation During Childhood in Familial Hypercholesterolemia: Importance of Genetic Diagnosis","volume":"253","author":"Peretti","year":"2023","journal-title":"J Pediatr"},{"key":"2026090910201091000_archdischild-2026-331003v1.37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MED.0000000000000706","article-title":"New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia","volume":"29","author":"Pirillo","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026090910201091000_archdischild-2026-331003v1.38","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-025-01299-7","article-title":"Oral PCSK9 Inhibitors: Will They Work?","volume":"27","author":"Tokg\u00f6zo\u011flu","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"2026090910201091000_archdischild-2026-331003v1.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100993","article-title":"Implementation strategies for improving the care of familial hypercholesterolaemia from the International Atherosclerosis Society: next steps in implementation science and practice","volume":"22","author":"Sarkies","year":"2025","journal-title":"Am J Prev Cardiol"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2026-331003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:20:20Z","timestamp":1788974420000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2026-331003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":39,"alternative-id":["10.1136\/archdischild-2026-331003"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2026-331003","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}